乳腺癌TOP2A基因与蒽环类药物疗效  

Current research status of TOP2A gene with response to anthracycline-based chemotherapeutic agents in breast cancer

作　　者：李绪渊[1] 李蔚冰[1] 林英城[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院内科,515031

出　　处：《国际肿瘤学杂志》2011年第2期127-129,共3页Journal of International Oncology

摘　　要：含蒽环类方案目前广泛应用于乳腺癌的治疗,其疗效与拓扑异构酶Ⅱ（TOP2）基因的异常状态存在关联,已有临床研究表明HER2基因扩增伴有TOP2基因异常的患者是蒽环类治疗的主要受益人群,但该结论未达成共识.Anthracycline-based chemotherapeutic agents were extensively applied to the treatment of breast cancer. The relation of its response to TOP2A gene was proved by a number of clinical studies demonstrating that patients with both HER2 gene amplification and TOP2A gene aberration have a favored outcome,but a consensus was not yet achieved.

关 键 词：乳腺肿瘤 DNA拓扑异构酶类 Ⅱ型 蒽环类 

分 类 号：R737.9[医药卫生—肿瘤]